Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CD13 Double Nickase Plasmid (h): sc-401095-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD13 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CD13 Double Nickase Plasmid (h) and CD13 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting ANPEP. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD13 Antibody (H-8): sc-166105
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD13 Double Nickase Plasmid (h) | sc-401095-NIC | 20 µg | $410.00 | |||
CD13 Double Nickase Plasmid (h2) | sc-401095-NIC-2 | 20 µg | $410.00 |
ANPEP encodes CD13, a zinc-dependent membrane alanyl aminopeptidase expressed on myeloid cells, endothelial compartments, and diverse epithelial tissues where it regulates extracellular peptide processing and amino acid supply. CD13 participates in proteolytic control of bioactive peptides and interfaces with cell adhesion, motility, and microenvironment remodeling, linking enzymatic activity to inflammatory signaling and tissue homeostasis. Through effects on leukocyte trafficking, angiogenic responses, and protease networks, CD13 is frequently used as a functional marker for myeloid differentiation and cellular activation states. Dysregulated ANPEP/CD13 expression or activity has been associated with altered immune cell behavior and tumor-associated stromal interactions, supporting mechanistic studies in inflammation and cancer biology.
CD13 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the ANPEP locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within ANPEP. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt ANPEP function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of ANPEP-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.